-
Mashup Score: 1
Gilead has announced that its investigational long-acting HIV-1 capsid inhibitor, lenacapavir, has achieved its primary endpoint in a phase 2/3 CAPELLA trial.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
Gilead has announced that its investigational long-acting HIV-1 capsid inhibitor, lenacapavir, has achieved its primary endpoint in a phase 2/3 CAPELLA trial.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
A recent Phase 2/3 Capella trial conducted by #Gilead Sciences, Inc. on its investigational, long-acting HIV-1 capsid inhibitor, #lenacapavir, has reached its primary endpoint, the company announced. https://t.co/6PQw6sjfCx
-
-
Mashup Score: 1
President Trump has already received multiple treatments since his COVID-19 diagnosis last week. Here we explain what they are and how they work.
Categories: Future of Medicine, Latest HeadlinesTweet-
.@realDonaldTrump is now leaving Walter Reed Medical Center after receiving multiple treatments since his #COVID19 diagnosis last week. Here we explain what they are and how those treatments work: https://t.co/hMeRXIa3qW #gilead #regeneron #trumpcovid #sciencetwitter #donaldtrump https://t.co/PXZmQHgkf8
-
-
Mashup Score: 0Gilead Sciences buying Immunomedics in $21 billion deal - 4 year(s) ago
Immunomedics’ drug Trodelvy was granted accelerated approval by the U.S. Food and Drug Administration in April for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.
Source: Modern HealthcareCategories: General Medicine News, Latest HeadlinesTweet-
Shares of the cancer drug specialist #Immunomedics more than doubled before the market opened Monday, a day after its sale to #Gilead Sciences for $21 billion was announced. #healthcare https://t.co/DNLPVNByb1
-
-
Mashup Score: 0Gilead releases another round of murky remdesivir results - 4 year(s) ago
A month after the NIH declared the first trial on remdesivir in Covid-19 a success, Gilead is out with new results on their antiviral. But although the study met one of its primary endpoints, the data are likely to only add to a growing debate over how effective the drug
Source: Endpoints NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
ICYMI: #Gilead releases another round of murky #remdesivir results https://t.co/ZVP9tHmFzD "The data 'continue to indicate a very marginal clinical benefit, while reinforcing that a benefit is likely more than random noise,'"
-
-
Mashup Score: 0
Generics companies will be able to set their own prices, but won’t have to pay Gilead royalties until the WHO declares an end to the health emergency.
Source: STATCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Gilead signs licenses for generic companies to make and sell #remdesivir in 127 countries https://t.co/xFy6H5x0Zl via @statnews $GILD the deals cover mostly low-income and lower-middle income countries
-
-
Mashup Score: 0The Cancer News Daily - 4 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/xxOYCMJvfH Thanks to @HemOncToday @Lymphomation #cureconnect #gilead
-
-
Mashup Score: 47
The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients in China with Covid-19 or prevent them from dying.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
Data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients.. https://t.co/EZijreGBKO #pharma #coronavirus #COVID19 $GILD #remdesivir
-
Eagle-eyed Ed Silverman @pharmalot spotted some #remdesivir data today from a Chinese study that ended early & showed no benefit. #Gilead says the report mischaracterized what was seen. Ed, @adamfeuerstein & @matthewherper assess. https://t.co/xkLGMbUEC8
-
-
Mashup Score: 0
Shares of Gilead Sciences Inc. undefined gained 0.4% in trading on Monday after BMO Capital Markets downgraded the stock to market perform from outperform….
Source: MarketWatchCategories: Healthcare Professionals, Latest HeadlinesTweet-
BMO downgrades #Gilead over concerns about commercial promise of #remdesivir. $GILD https://t.co/brbtMh1GNP A #Hydroxychloroquine-variety debate redux. It may take as long to get these resolved as to make a reliable #vaccine.
-
-
Mashup Score: 0Gilead Says It’s Too Soon to Draw Conclusions on Its Coronavirus Drug. Analysts Say the Market Is Overreacting, Too. - 4 year(s) ago
The major U.S. stock indexes took off in response to a report about the drug on Thursday evening.
Source: www.barrons.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Gilead $GILD Says It’s Too Soon to Draw Conclusions on Its #Coronavirus Drug. Analysts Say the Market Is Overreacting, Too. https://t.co/bjHnkeWaYH via @BarronsOnline Is this another #hydroxychroloquine-variety debate.. ?
-
#Gilead announced this week that its investigational long-acting HIV-1 capsid inhibitor, #lenacapavir, has achieved its primary endpoint in a phase 2/3 CAPELLA trial. #HIV https://t.co/6PQw6s1EKZ